期刊文献+

β-雌二醇聚氰基丙烯酸正丁酯纳米粒制备工艺的研究 被引量:7

Study on the preparing technology of β-estradiol polybutylcyanoacrylate nanoparticles
下载PDF
导出
摘要 目的制备β-雌二醇聚氰基丙烯酸正丁酯纳米粒(E2-PBCA-NP),考察影响纳米粒粒径大小、包封率的因素,并优化其制备条件。方法以氰基丙烯酸正丁酯为载体,采用界面聚合的方法制备E2-PB-CA-NP,以粒径大小、形态和包封率为指标,通过单因素试验初选,正交设计法优化E2-PBCA-NP制备工艺。结果搅拌速度、浓缩温度、有机溶剂种类及表面活性剂类型均可影响粒径。按优化工艺条件,制得的载药纳米粒平均粒径为115nm,分布范围50~180nm,包封率90.3%。结论经过优化筛选出的工艺,为制备E2-PB-CA-NP的最佳工艺。 [Objective] To prepare beta-estradiol polybutylcyanoacrylate nanoparficles (E2-PBCA-NP), study the factors affecting the particle size and the envelope rate, and optimize the preparing technology. [Method] E2- PBCA-NP was prepared by interracial polymerization with the butyleyanoaerylate as its carrier, the preparing technology was optimized by single factor test and orthogonal design test with particle size and the envelope rate as the test standard. [ Result] Various parameters including stirrlng rate, reaction temperature, organic solvent and the kind of surfaetas, could affect the particle size. Under the optimum condition, the average diameter of the nanoparticle was 115 nm, the distributing range between 50 and 180 nm, the envelope rate(90.3%). [Conclusion] The optimized technology is the best one in preparing E2-PBCA-NP.
出处 《中国医学工程》 2006年第5期452-455,共4页 China Medical Engineering
基金 湖南省自然科学基金(No:03JJY3060)
关键词 Β-雌二醇 纳米粒 聚氰基丙烯酸正丁酯 正交设计 beta-estradiol nanoparticles polybutylcyanoaerylate orthogonal- design
  • 相关文献

参考文献11

  • 1张阳德,李浩.纳米载体肝靶向纳米药物研究进展[J].中国医学工程,2003,11(6):75-77. 被引量:10
  • 2[2]ILLUM L,DAVIS SS,MULLER RH,et al.The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908[J].Life Sci,1987,40(4):367-374.
  • 3[3]VAUTHIER C,DUBERNET C,FATTAL E,et al.Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications[J].Adv Drug Deliv Rev,2003,55(4):519-548.
  • 4[4]SIMEONOVA M,CHORBADJIEV K.ANTCHEVA M.Study of the effect of polybutylcyanoacrylate nanoparticles and their metabolites on the primary immune response in mice to sheep red blood cells[J].Biomaterials,1998,19(23):2187-2193.
  • 5[5]MIYAZAKI S,TAKAHASHI A,KUBO W,et al.Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs:in vitro release and in vivo skin penetration[J].J Pharm Pharm Sci,2003,6(2):238-245.
  • 6[6]PUGLISI G,FRESTA M,GIAMMONA G,et al.Influence of the preparation conditions on poly(ethylcyanoacrylate) nanocapsule formation[J].International Journal of Pharmaceutics,1995,125(2):283-287.
  • 7[7]PERACCHIA MT,VAUTHIER C,DESMAELE D,et al.Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer[J].Pharm Res,1998,15(4):550-556.
  • 8[8]VANDELLI MA,FRESTA M,PUGLISI G,et al.An interpretative analysis of the effect of the surfactants used for the preparation of polyalkylcyanoacrylate nanoparticles on the release process[J].J Microencapsul,1994,11(5):531-538.
  • 9[9]CHOUINARD F,KAN FWK,LEROUX J-C,et al.Preparation and purification of polyisohexylcyanoacrylate nanocapsules[J].International Journal of Pharmaceutics; 1991,72(3):211-217.
  • 10[10]REDDY LH,MURTHY RR.Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly (butylcyanoacrylate)nanoparticles[J].Acta Pharm,2004,54(2):103-118.

二级参考文献2

共引文献9

同被引文献67

引证文献7

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部